Murray Epstein

18.2k total citations · 5 hit papers
261 papers, 13.3k citations indexed

About

Murray Epstein is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Nephrology. According to data from OpenAlex, Murray Epstein has authored 261 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Cardiology and Cardiovascular Medicine, 85 papers in Pulmonary and Respiratory Medicine and 78 papers in Nephrology. Recurrent topics in Murray Epstein's work include Blood Pressure and Hypertension Studies (64 papers), Electrolyte and hormonal disorders (47 papers) and Renal function and acid-base balance (37 papers). Murray Epstein is often cited by papers focused on Blood Pressure and Hypertension Studies (64 papers), Electrolyte and hormonal disorders (47 papers) and Renal function and acid-base balance (37 papers). Murray Epstein collaborates with scholars based in United States, Canada and Japan. Murray Epstein's co-authors include James R. Sowers, Rodger Loutzenhiser, Edward D. Fröhlich, Vicente Arroyo, Joan Rodés, Jens H. Henriksen, Mauro Bernardi, Kôichi Hayashi, Robert W. Schrier and George L. Bakris and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Investigation.

In The Last Decade

Murray Epstein

257 papers receiving 12.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis

1988 1.2k citations Robert W. Schrier, Vicente Arroyo et al. Hepatology profile →
Preserving renal function in adults with hypertension and diabetes: A consensus approach

2000 1.1k citations George L. Bakris, Murray Epstein et al. American Journal of Kidney Diseases profile →
Diabetes, Hypertension, and Cardiovascular Disease

2001 1.0k citations Murray Epstein et al. profile →
Renin-Angiotensin System Blockers and the COVID-19 Pandemic

2020 354 citations Murray Epstein et al. profile →
Renal failure in the patient with cirrhosis

1970 344 citations Murray Epstein et al. profile →

Peers

Countries citing papers authored by Murray Epstein

Since Specialization

Citations

This map shows the geographic impact of Murray Epstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray Epstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray Epstein more than expected).

Fields of papers citing papers by Murray Epstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murray Epstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray Epstein. The network helps show where Murray Epstein may publish in the future.

Co-authorship network of co-authors of Murray Epstein

This figure shows the co-authorship network connecting the top 25 collaborators of Murray Epstein. A scholar is included among the top collaborators of Murray Epstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murray Epstein. Murray Epstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The constellation of vitamin D, the acute-phase response, and inflammation 2023 ·Cleveland Clinic Journal of Medicine ·Maria Antonelli, Irving Kushner, Murray Epstein	5
2	Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials 2023 ·American Journal of Kidney Diseases ·David A. Bushinsky, (unknown), Philip A. Kalra, Jinwei Yuan, (unknown), Murray Epstein	6
3	The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets 2022 ·Kidney International Supplements ·Morley D. Hollenberg, Murray Epstein	13
4	Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD 2021 ·Clinical Journal of the American Society of Nephrology ·Murray Epstein, Roberto Pecoits‐Filho, Catherine M. Clase, Manish M. Sood, Csaba P. Kövesdy	10
5	Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and Dampers 2021 ·Kidney International Reports ·Murray Epstein	5
6	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future 2016 ·Pharmacological Research ·Patrick Rossignol, Matthieu Legrand, Mikhail Kosiborod, Steven M. Hollenberg, W. Frank Peacock, Michael Emmett, Murray Epstein, Csaba P. Kövesdy, Mehmet Birhan Yılmaz, Wendy Gattis Stough, Étienne Gayat, Bertram Pitt, Faı̈ez Zannad, Alexandre Mebazaa	90
7	Hyperkalemia: current concepts and emerging therapeutic options 2016 ·Kidney International Supplements ·Murray Epstein	2
8	Abstract 14271: Patiromer Controls Hyperkalemia in Resistant Hypertensive Patients on RAASi, With Diabetic Kidney Disease 2015 ·Circulation ·Murray Epstein, Martha Mayo, Dahlia Garza, Yuri Stasiv, (unknown), Lance Berman, (unknown), George L. Bakris	6
9	Fixed-dose combination therapy with calcium antagonists. 2002 ·IRIS ·Murray Epstein, B. Waeber	2
10	Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study 2002 ·Journal of Human Hypertension ·George L. Bakris, Amy C. Smith, (unknown), (unknown), Richard A. Preston, Ronald Goldberg, Murray Epstein	27
11	Evolving therapeutic strategies for retarding progression of diabetic nephropathy - an update for 2002 2002 ·Acta Diabetologica ·Murray Epstein	4
12	The Growing Role of Calcium Antagonists in Treating Hypertension in the Elderly 2000 ·The American Journal of Geriatric Cardiology ·Murray Epstein	3
13	The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects 1999 ·Critical Care Medicine ·Vandana Mathur, Suzanne K. Swan, Lawrence J. Lambrecht, Shakeel Anjum, J. D. FELLMANN, Dawn McGuire, Murray Epstein, Robert R. Luther	129
14	A symposium : calcium antagonists and the diabetic patient : recent controversies and future perspectives 1998 ·Murray Epstein	1
15	Calcium antagonists and renal disease 1998 ·Kidney International ·Murray Epstein	23
16	Video-microscopic Assessment of the Role of Tissue Angiotensin-converting Enzyme in the Control of the Renal Microcirculation 1997 ·Journal of Pharmacology and Experimental Therapeutics ·Pieter M. ter Wee, H Förster, Murray Epstein	4
17	The Kidney in liver disease 1996 ·Murray Epstein	107
18	Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis breakdown → 1988 ·Hepatology ·Robert W. Schrier, Vicente Arroyo, Mauro Bernardi, Murray Epstein, Jens H. Henriksen, Joan Rodés	1187
19	Renal sodium handling in cirrhosis 1983 ·Seminars in Nephrology ·Murray Epstein	21
20	Alterations in acid-base homeostasis during water immersion in normal man 1974 ·Journal of Laboratory and Clinical Medicine ·Murray Epstein, (unknown), Carlos A. Vaamonde	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact